These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 12176559)
1. Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. Koefoed-Nielsen PB; Jørgensen KA Transplant Proc; 2002 Aug; 34(5):1743-4. PubMed ID: 12176559 [No Abstract] [Full Text] [Related]
2. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection. Fukudo M; Yano I; Katsura T; Ito N; Yamamoto S; Kamoto T; Ogawa O; Inui K Drug Metab Pharmacokinet; 2010; 25(5):411-7. PubMed ID: 20834189 [TBL] [Abstract][Full Text] [Related]
3. Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. Sato S; Fuchinoue S; Tojimbara T; Fujita S; Nakajima I; Agishi T; Hayashi T; Teramura Y; Fujita E; Iwasaki K Transplant Proc; 1998 Jun; 30(4):1274-5. PubMed ID: 9636517 [No Abstract] [Full Text] [Related]
4. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Koefoed-Nielsen PB; Gesualdo MB; Poulsen JH; Jørgensen KA Am J Transplant; 2002 Feb; 2(2):173-8. PubMed ID: 12099520 [TBL] [Abstract][Full Text] [Related]
5. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Pisitkun T; Eiam-Ong S; Chusil S; Praditpornsilpa K; Pansin P; Tungsanga K Transplant Proc; 2002 Dec; 34(8):3173-5. PubMed ID: 12493410 [No Abstract] [Full Text] [Related]
6. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Uchida K; Tominaga Y; Haba T; Katayama T; Matsuoka S; Sato T; Goto N; Takeda A; Morozumi K; Takagi H Transplant Proc; 2002 Aug; 34(5):1736-7. PubMed ID: 12176556 [No Abstract] [Full Text] [Related]
7. Monitoring calcineurin inhibitor therapy: localizing the moving target. Naesens M; Sarwal MM Transplantation; 2010 Jun; 89(11):1308-9. PubMed ID: 20458272 [No Abstract] [Full Text] [Related]
8. The calcineurin activity profiles of cyclosporin and tacrolimus are different in stable renal transplant patients. Koefoed-Nielsen PB; Karamperis N; Højskov C; Poulsen JH; Jørgensen KA Transpl Int; 2006 Oct; 19(10):821-7. PubMed ID: 16961774 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. Braun F; Lorf T; Schütz E; Christians U; Grupp C; Sattler B; Canelo R; Sewing KF; Armstrong VW; Oellerich M; Ringe B Transplant Proc; 1996 Dec; 28(6):3175-6. PubMed ID: 8962231 [No Abstract] [Full Text] [Related]
10. Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up. Brunet M; Torregrosa JV; Oppenheimer F; Corbella J Transplant Proc; 1998 Dec; 30(8):4068-9. PubMed ID: 9865298 [No Abstract] [Full Text] [Related]
11. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Undre NA; Schäfer A Transplant Proc; 1998 Jun; 30(4):1261-3. PubMed ID: 9636512 [No Abstract] [Full Text] [Related]
12. Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. Yano I Drug Metab Pharmacokinet; 2008; 23(3):150-7. PubMed ID: 18574318 [TBL] [Abstract][Full Text] [Related]
13. High QT dispersion in tacrolimus-treated kidney transplant recipients. Gerhardt U; Suwelack B; Pawolka A; Hohage H Transplant Proc; 2001 May; 33(3):2148-50. PubMed ID: 11377482 [No Abstract] [Full Text] [Related]
14. Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients. Jørgensen KA; Povlsen JV; Madsen S; Madsen M; Hansen HE; Pedersen AR; Heinsvig EM; Poulsen JH Transplant Proc; 2002 Aug; 34(5):1721-2. PubMed ID: 12176551 [No Abstract] [Full Text] [Related]
15. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. Hesse CJ; Baan CC; Balk AH; Metselaar HJ; Weimar W; van Gelder T Transplant Proc; 2002 Nov; 34(7):2988-90. PubMed ID: 12431679 [No Abstract] [Full Text] [Related]
16. Effects of immunosuppressive regimens on plasma levels of transforming growth factor-beta 1 in renal transplant recipients. Pozzetto U; Citterio F; Romagnoli J; Scatà M; Nanni G; Castagneto M Transplant Proc; 2002 Aug; 34(5):1740-2. PubMed ID: 12176558 [No Abstract] [Full Text] [Related]
17. Analysis of factors influencing tacrolimus levels and immunoassay bias in renal transplantation. Borrows R; Chusney G; Loucaidou M; James A; Goel S; Borrows S; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D J Clin Pharmacol; 2007 Aug; 47(8):1035-42. PubMed ID: 17660485 [No Abstract] [Full Text] [Related]
18. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. Koefoed-Nielsen PB; Karamperis N; Jørgensen KA Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449 [TBL] [Abstract][Full Text] [Related]
19. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Webb NJ; Stevenson PJ; Lewis MA; Postlethwaite RJ; Bradbury MG; Undre N Transplant Proc; 2002 Aug; 34(5):1948-50. PubMed ID: 12176639 [No Abstract] [Full Text] [Related] [Next] [New Search]